A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

CME America Announces a Follow-Up on the Voluntary Recall of BodyGuard® Infusion System Administration Sets

July 3, 2020

CME America, a wholly-owned subsidiary of BD, announced a voluntary recall for all CME America BodyGuard® Infusion System Administration Sets (infusion sets)—used with the company’s BodyGuard® infusion pumps—that were distributed beginning May 2016 (see complete impacted product list below).  This action was initiated on June 16, 2020.

As part of CME America’s commitment to quality, following the previously announced recall (April 27, 2020) of the BodyGuard® Infusion Pump Systems, the company conducted additional flow-rate accuracy testing. This testing revealed that some infusion sets do not meet the ±5% delivery accuracy for the system or the ±13% accuracy identified in the earlier recall notification. Therefore, the use of the pump system potentially could cause over-infusion or under-infusion of therapy and patient harm.

Based on those test results CME America is providing additional information and customer actions regarding its previous recall to include all infusion sets used with the BodyGuard® infusion pump distributed beginning May 2016. CME America has defined four categories of impacted infusion sets based on delivery inaccuracy variability, two of which (Category A and B) can continue to be used in accordance with the instructions in the recall letter.

CME America also announced on April 27, 2020, the decision to suspend distribution of the BodyGuard® infusion pumps and to remove all existing products from the U.S. market. CME America will work with customers to address the latest expanded infusion set recall and will continue to maintain continuity of care during the COVID-19 pandemic.  Until such time that the BodyGuard® pumps have been removed from the market, CMEA will supply accessories and infusion sets in “Category A” and “Category B” to support the infusion pumps, and customers can continue to use the products in accordance with the Operator’s Manual and the additional mitigations outlined in the customer letter.

Affected Product Types

BodyGuard BodySet

BodyGuard Microset with Needleless Adaptor

BodyGuard Microsets

BodyGuard Microset w/ Non-Vented Spike Connector

BodyGuard set with Female Luer

BodyGuard Microset w/ 0.2 mic filter and lower y-site with female luer

BodyGuard Microsets with Filter

Standard BodySet with Needleless Connectors

BodyGuard Microset with Filter and Manual Priming Valve

CMExpress Microbore Sets

BodyGuard Microset with Male Luer Connectors

CMExpress Needleless Y Site Microbore Set

See Customer Notification for full list of Affected Product Codes

Customer inquiries related to either recall, as well as adverse reaction/events experienced with the product should be addressed to CME America Support Center at 877-263-0111.

FDA MedWatch Reporting

FDA has been notified of this recall. Adverse reactions/events experienced with the use of any of these products should also be reported to the FDA’s MedWatch Program by:

  • Web: MedWatch website at www.fda.gov/medwatch
  • Phone: 1-800-FDA-108
  • Fax: 1-800-FDA-0178
  • Mail: MedWatch, HF-2, FDA, 5600 Fishers Lane, Rockville, MD 20852-9787

 

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy